Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$6.05

-5.035 (-45.44%)

07:27
06/12/19
06/12
07:27
06/12/19
07:27

CymaBay selloff yesterday brings buying opportunity, says Cantor Fitzgerald

Cantor Fitzgerald analyst Eliana Merle says the selloff yesterday in shares of CymaBay Therapeutics strengthens her conviction and presents a buying opportunity. The 52-week biopsy data in early 2020 "remain very much in play from a scientific perspective, but now with much greater upside potential from a stock perspective," Merle tells investors in a research note. While the analyst found the lack of fat benefit at week 12 surprising, she says her thesis on seladelpar in nonalcoholic steatohepatitis is that there are many biological reasons why the drug could show "strong" 52-biopsy data independent of fat changes. There is undue investor focus on MRI-PDFF, making NASH a "very large piece of optionality early next year," says the analyst. Merle reiterates an Overweight rating on CymaBay with a $20 price target. The stock closed yesterday down 45%, or $5.04, to $6.05.

  • 12

    Jun

CBAY CymaBay
$6.05

-5.035 (-45.44%)

05/14/19
SBSH
05/14/19
INITIATION
Target $21
SBSH
Buy
CymaBay initiated with a Buy at Citi
Citi analyst Joel Beatty started CymaBay Therapeutics (CBAY) with a Buy rating and $21 price target. The analyst believes the company's seladelpar will "likely dethrone" Intercept Pharmaceuticals' (ICPT) Ocaliva as the top-selling branded primary biliary cholangitis drug. Topline results for seladelpar in PBC are anticipated in 2021 and the analyst sees a 75% probability of approval.
06/07/19
LEER
06/07/19
NO CHANGE
Target $22
LEER
Outperform
FDA news has 'nothing to do' with CymaBay's programs, says SVB Leerink
SVB Leerink analyst Pasha Sarraf says that CymaBay Therapeutics is down on an "overreaction" to the FDA's recommendation regarding endpoint for compensated cirrhosis. In a research note to investors , Sarraf says he recommends purchasing at these levels, saying he continues to believe the the stock is likely to pop on the interim results from the MRI-PDFF results, which have not yet been announced and feels the FDA's announcement regarding compensated cirrhosis has "absolutely nothing to do" with CymaBay's programs. Sarraf has an Outperform rating and $22 price target on CymaBay shares.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $8
PIPR
Overweight
Piper cuts CymaBay price target to $8 on 'worst case' results for NASH trial
Piper Jaffray analyst Tyler Van Buren said he did not anticipate that placebo would perform better than seladelpar in CymaBay Therapeutics' (CBAY) Phase 2b study of the drug for the treatment of nonalcoholic steatohepatitis. Calling the NASH trial results a "worst case scenario," Van Buren sees significant risk to the final 52-week data read-out and removed all expectations in NASH from his model. He said the data make seladelpar seem similar to Genfit's (GNFT) elafibranor, though seladelpar has not yet shown improvements in good cholesterol, glucose homeostatis, or insulin resistance. While Van Buren cut his price target on CymaBay shares to $8 from $30 based on the trial results, he keeps an Overweight rating on the shares given the sharp pullback this morning and the support he sees from the company's remaining cash and residual opportunity.
06/11/19
RAJA
06/11/19
UPGRADE
Target $19
RAJA
Strong Buy
CymaBay upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded CymaBay to Strong Buy from Outperform citing the upside potential he sees following today's pullback in the stock. He keeps a $19 price target on the shares, calling today's reaction to the surrogate endpoint data "overblown."

TODAY'S FREE FLY STORIES

CURLF

Curaleaf Holdings

$0.00

(0.00%)

08:07
06/27/19
06/27
08:07
06/27/19
08:07
Hot Stocks
Curaleaf Holdings makes two separate acquisitions in Arizona for $25.5M »

Curaleaf Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATOS

Atossa Genetics

$2.27

-0.035 (-1.52%)

08:07
06/27/19
06/27
08:07
06/27/19
08:07
Hot Stocks
Atossa says preliminary Phase 2 study of Endoxifen achieves primary endpoint »

Atossa Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$23.19

1 (4.51%)

08:06
06/27/19
06/27
08:06
06/27/19
08:06
Initiation
Adient initiated  »

Adient initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANF

Abercrombie & Fitch

$15.85

0.49 (3.19%)

08:05
06/27/19
06/27
08:05
06/27/19
08:05
Hot Stocks
Green Growth Brands expands partnership with Abercrombie & Fitch »

Green Growth Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZGNX

Zogenix

$39.43

-0.07 (-0.18%)

08:05
06/27/19
06/27
08:05
06/27/19
08:05
Hot Stocks
Zogenix announces FDA agreement to proceed with resubmission of FINTEPLA NDA »

Zogenix announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
06/27/19
06/27
08:05
06/27/19
08:05
General news
U.S. initial jobless claims preview: initial claims are expected to rise 5k to 221k »

U.S. initial jobless…

08:05
06/27/19
06/27
08:05
06/27/19
08:05
General news
U.S. Q1 GDP preview: w »

U.S. Q1 GDP preview:…

HTH

Hilltop Holdings

$20.05

0.26 (1.31%)

08:03
06/27/19
06/27
08:03
06/27/19
08:03
Hot Stocks
Hilltop Holdings signs sponsored research agreement with GWU »

Hoth Therapeutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Aug

HQY

HealthEquity

$62.16

-2.5 (-3.87%)

08:03
06/27/19
06/27
08:03
06/27/19
08:03
Conference/Events
HealthEquity to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

ALRN

Aileron Therapeutics

$0.75

-0.0365 (-4.63%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Hot Stocks
Aileron Therapeutics announces FDA acceptance of IND for ALRN-6924 »

Aileron Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$375.05

5.68 (1.54%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Recommendations
Boeing analyst commentary  »

BofA continues to see 6-9…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 24

    Jul

CABO

Cable One

$1,111.46

-18.95 (-1.68%)

08:02
06/27/19
06/27
08:02
06/27/19
08:02
Recommendations
Cable One analyst commentary  »

Cable One price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VFC

VF Corp.

$85.74

0.32 (0.37%)

08:01
06/27/19
06/27
08:01
06/27/19
08:01
Recommendations
VF Corp. analyst commentary  »

VF Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

TSLA

Tesla

$219.22

-0.47 (-0.21%)

08:00
06/27/19
06/27
08:00
06/27/19
08:00
Options
Tesla put buyer realizes 36% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$119.01

-1.3 (-1.08%)

07:57
06/27/19
06/27
07:57
06/27/19
07:57
Recommendations
Coupa Software analyst commentary  »

Coupa Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

BB

BlackBerry

$7.55

-0.74 (-8.93%)

07:56
06/27/19
06/27
07:56
06/27/19
07:56
Recommendations
BlackBerry analyst commentary  »

BlackBerry execution…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SM

SM Energy

$12.56

0.63 (5.28%)

07:55
06/27/19
06/27
07:55
06/27/19
07:55
Initiation
SM Energy initiated  »

SM Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

07:55
06/27/19
06/27
07:55
06/27/19
07:55
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

ITRI

Itron

$60.88

0.48 (0.79%)

07:55
06/27/19
06/27
07:55
06/27/19
07:55
Conference/Events
Itron to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

XEC

Cimarex Energy

$57.17

1.64 (2.95%)

07:53
06/27/19
06/27
07:53
06/27/19
07:53
Initiation
Cimarex Energy initiated  »

Cimarex Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

COUP

Coupa Software

$119.01

-1.3 (-1.08%)

07:52
06/27/19
06/27
07:52
06/27/19
07:52
Recommendations
Coupa Software analyst commentary  »

Coupa Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jul

LECO

Lincoln Electric

$79.77

0.1 (0.13%)

07:52
06/27/19
06/27
07:52
06/27/19
07:52
Downgrade
Lincoln Electric rating change  »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$42.13

0.455 (1.09%)

07:50
06/27/19
06/27
07:50
06/27/19
07:50
Conference/Events
Eaton Vance to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBC

Luther Burbank

$10.33

-0.13 (-1.24%)

07:50
06/27/19
06/27
07:50
06/27/19
07:50
Upgrade
Luther Burbank rating change at Sandler ONeill »

Luther Burbank upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$20.29

0.54 (2.73%)

07:49
06/27/19
06/27
07:49
06/27/19
07:49
Hot Stocks
Qiwi appoints Vladislav Poshmorga as CFO »

QIWI announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.